NASA Hospitals is an asset-light specialty healthcare operator that acquires distressed 75-100 bed mid-market hospitals in India and converts them into single-specialty focused centres. The sponsor brings direct operational track record — 150 beds already operating across 3 hospitals — and deploys a proven 12-18 month turnaround playbook that brings targets from negative EBITDA to 25%+ EBITDA margins.
The $40M raise capitalises the platform's scaling phase, targeting a 1,000-bed network in 5 years through both organic conversion and the Remedy Hospitals (pitched as Asterix) Hyderabad flagship acquisition.
Four specialty verticals define NASA's operating focus:
The 12-18 month turnaround playbook brings distressed targets from negative EBITDA to 25%+ margins through four operating levers: (1) specialty focus driving case-mix improvement and ARPOB expansion; (2) bulk procurement cost reduction (~12%); (3) elimination of related-party-transaction markups; (4) capital-structure refinancing at institutional rates.
India's Specialty Healthcare Gap
India's mid-market hospital segment is fragmented and under-professionalised. Distressed 75-100 bed assets are available at 30%+ discounts to sector multiples (Apollo/Max trade at 15-16× stabilised EBITDA). The arbitrage: acquiring at 11-12× distressed EBITDA and exiting at 16-18× stabilised — while patients benefit from corporate-grade care at 20-30% lower cost.
Single-Specialty Model Advantage
Single-specialty focus (Neuro, Spine, Ortho, Critical Care) drives higher ARPOB (average revenue per occupied bed) vs. general-care competitors. Case-mix optimisation lets NASA target the 20% of procedures driving 80% of hospital revenue — a proven model validated across NASA's existing 150-bed platform.
Flagship Acquisition — Remedy Hospitals Hyderabad
80% acquisition at ₹55 Cr equity / ₹80 Cr EV (~11.8× FY26 EBITDA) — a 30% discount to sector. Capital stack: PE 49% / NASA 31% / Remedy promoters retain 20% for alignment. Use of equity: ₹10 Cr promoter buyout · ₹15 Cr debt refinancing · ₹10 Cr working capital · ₹5 Cr capex · ₹15 Cr NASA platform consolidation. Value creation bridge: FY26 EBITDA ₹6.8 Cr → FY29 EBITDA ₹27 Cr. Exit: IPO at 16-18× → 2.8-3.2× MoIC · 26-30% IRR.
Multi-Layer Security
① Operating cash flows — 150 beds currently operating, validated unit economics
② Acquisition discount — 30% below sector multiples on entry
③ Promoter retention — selling promoters retain 20% for execution alignment
④ Exit liquidity — Indian healthcare IPO market active at 15-18× stabilised EBITDA
| Scenario | FY29 EBITDA | Exit Multiple | Exit EV | Equity Value | MoIC | IRR |
|---|---|---|---|---|---|---|
| Base | ₹24 Cr | 16x | ₹384 Cr | ₹160 Cr | 2.9x | 27% |
| Upside | ₹27 Cr | 18x | ₹486 Cr | ₹210 Cr | 3.8x | 33% |
| Downside | ₹20 Cr | 14x | ₹280 Cr | ₹120 Cr | 2.2x | 21% |
NASA Hospitals' leadership team combines specialty clinical expertise with institutional healthcare M&A experience. The management bench includes medical directors overseeing the four specialty verticals (Neuro, Spine, Ortho, Critical Care), financial operators leading acquisition due diligence and post-close integration, and corporate leadership overseeing the 5-year scaling trajectory to 1,000 beds.
Detailed leadership profiles and medical director bios available on the Business Plan page.